ASCO 2012 Report – Early, highly promising results for Crizotinib (Xalkori) in three aggressive pediatric cancers
by Bruce Sylvester – In a phase I study presented at ASCO, researchers reported that crizotinib (Xalkori) stalled tumor growth and, in some cases, eradicated all signs of… read more.




